Epilepsy program (AMT-260) -- An update in Q2 is expected to present six-month data from the first six patients in the initial dose cohort, with data focused on seizure frequency, safety, and ...

Held Type A meeting with FDA to discuss AMT-130 for Huntington’s disease; Company evaluating Phase III development considerations and plans to ...

However, traditional clinical trial designs are often ill-suited for rare disease research with common challenges including ...

Q4 2025 Earnings Call February 26, 2026 8:30 AM ESTCompany ParticipantsLuis Sanay - Vice President of Investor RelationsJohn Jacobs ...

After a decade of its stock hovering in a consistent range, Hyundai Motor is eying an explosive increase in its market ...

To further complicate clinicians’ treatment decisions, Padcev-Keytruda has become the new standard of care in first-line metastatic bladder cancer, raising the possibility that some physicians might ...

Yet another lawsuit has alleged that, “rather than acting with a singular focus on the needs of the Plan’s participants and beneficiaries, the Defendants ignored poor investment performance.” ...

No one can accuse Uniphar (UPR) of lacking ambition, as the Irish specialist distribution business continues to grow ...

Recent corporate filings referenced share activity and ongoing market participation. Cloud based enterprise software sits ...

Q4 2025 Earnings Call February 24, 2026 4:30 PM ESTCompany ParticipantsAndrew Guggenhime - President & CFOGrant Pickering ...

This article discusses precision fermentation, as well as the nutritional profile, sustainability, and applications of fermented fat products.

How do we take on and resolve vein-related pelvic pain in women? PeVD has been associated with venous-origin chronic pelvic ...